et al. Life after prostate cancer diagnosis: protocol for a UK-wide patient-reported outcomes study. BMJ Open 6, e013555 (2016).Downing A, Wright P, Wagland R, et al. Life after prostate cancer diagnosis: protocol for a UK-wide patient-reported outcomes study. BMJ open 2016; 6: e...
J.S.d.B. acknowledges funding from Movember, Prostate Cancer UK, the Prostate Cancer Foundation, Cancer Research UK and the Medical Research Council. J.S.d.B. is a National Institutes of Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author...
AI-enabled Software To Detect Prostate Cancer Bone Metastases Clears FDA November 17, 2020 An artificial intelligence (AI) program that aims to make it easier to identify bone metastases ... News UK Study to Assess Causes of Greater Prostate Cancer Risk Among Black Men ...
Prostate cancer is a complex disease that affects millions of men globally, predominantly in high human development index regions. Patients with localized disease at a low to intermediate risk of recurrence generally have a favourable outcome of 99% over
This resource provides expert advice about prostate cancer to help you discuss key issues with your healthcare provider. Learn the facts about risk factors, symptoms, screening, diagnosis, and treatment through easy-to-understand animations, expert video
“These data clearly support the prognostic power of the ConfirmMDx genes. The addition of a risk score for ConfirmMDx methylated patients, which enhances the test’s positive predictive value, will provide deeper insights into a patient’s risk for undetected clinically significant cancer,” s...
clinically irrelevant tumors and benign abnormalities are also detected that can potentially lead to over-treatment and the associated physical as well as emotional burden for the patient. Furthermore, PSA is used as an indicator of progression or clinical response following prostate cancer therapy, bu...
For more information on how to reduce your prostate cancer risk, click here. Genetic There are a few genes that are associated with an increased risk of developing prostate cancer. These may explain why prostate cancer seems to run in some families. However, these genes are likely only to ...
“Twenty years ago, we were looking for any kind of [prostate] cancer," said Wei, a professor of urology at the university. "Now, we realize that slow-growing cancer doesn’t need to be treated. All of a sudden, the game changed. We went from having to find any cancer to finding ...
Advanced prostate and bladder cancer are two outstanding unmet medical needs for urological oncologists. The high prevalence of these tumours, lack of effective biomarkers and limited effective treatment options highlight the importance of basic research in these diseases. Galectins are a family of β...